Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00948922 · ClinicalTrials.gov registry record · Phase 2
Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma
A Phase 2 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
NCT00948922 is a Phase 2 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 124 participants.
The verdict
NCT00948922, a Phase 2 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness of Bortezomib when added to standard chemotherapy medicine(s) for treatment of Multiple Myeloma.
Interventions
- DRUG Fludarabine
- DRUG Melphalan
- DRUG Bortezomib
- PROCEDURE Autologous Stem Cell Transplant
- PROCEDURE Allogeneic Stem Cell Transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2009-06-18 |
| Est. Completion | 2019-05-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00948922
The ClinicalTrials.gov registry entry for NCT00948922 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.
NCT00948922 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00948922 about?
NCT00948922 is a clinical study titled "Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma". The purpose of this study is to evaluate the effectiveness of Bortezomib when added to standard chemotherapy medicine(s) for treatment of Multiple Myeloma.
What is the current status of trial NCT00948922?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2009-06-18. Estimated completion is 2019-05-14.
What interventions are being tested in trial NCT00948922?
The interventions under investigation include: Fludarabine (DRUG), Melphalan (DRUG), Bortezomib (DRUG), Autologous Stem Cell Transplant (PROCEDURE), Allogeneic Stem Cell Transplant (PROCEDURE).
Who is sponsoring clinical trial NCT00948922?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.